Risankizumab (Skyrizi)
AbbVie
Description
A humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds with high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor complex. IL-23 is a cytokine that is involved in inflammatory and immune responses. By blocking IL-23 from binding to its receptor, risankizumab inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines.
Indications
Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (alone or in combination with methotrexate)
Contraindications
Hypersensitivity to the active substance or to any of the excipients; clinically important active infections (e.g. active tuberculosis)
Price
Pre-filled injection pen, 150-360mg, £326.09
More on: Systemic psoriasis treatments